Monopar Therapeutics (MNPR) Equity Average (2018 - 2020)

Monopar Therapeutics' Equity Average history spans 3 years, with the latest figure at $14.8 million for Q3 2020.

  • For Q3 2020, Equity Average rose 204.01% year-over-year to $14.8 million; the TTM value through Sep 2020 reached $14.8 million, up 204.01%, while the annual FY2019 figure was $9.8 million, 18.19% up from the prior year.
  • Equity Average for Q3 2020 was $14.8 million at Monopar Therapeutics, up from $12.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $14.8 million in Q3 2020 and bottomed at $4.9 million in Q3 2019.
  • The 3-year median for Equity Average is $8.5 million (2018), against an average of $8.9 million.
  • The largest annual shift saw Equity Average tumbled 37.88% in 2019 before it soared 204.01% in 2020.
  • A 3-year view of Equity Average shows it stood at $7.2 million in 2018, then increased by 19.03% to $8.6 million in 2019, then soared by 71.83% to $14.8 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Equity Average are $14.8 million (Q3 2020), $12.3 million (Q2 2020), and $12.5 million (Q1 2020).